Track market-moving stories before they get noisy

-

Board of Directors approves quarterly cash dividend of $0.43 per share

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company’s common stock, payable September 1, 2026, to holders of the Common Stock of record at the close of business on July 24, 2026.

Pfizer is committed to maintaining, and over the longer term, growing the dividend, as part of its capital allocation strategy. The third-quarter 2026 cash dividend will be the 351st consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For over 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The information contained in this release is as of June 24, 2026. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking information about, among other things, Pfizer’s commitment to maintaining, and over the longer term, growing the dividend, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; risks associated with our clinical development plans; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; uncertainties regarding the ability to obtain or maintain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; risks related to the ability to realize the anticipated benefits of Pfizer’s business development transactions, including the possibility that the expected benefits from such transactions will not be realized or will not be realized within the expected time period; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment, trade policies or economies generally; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Category: Corporate, Financial

More News From Pfizer Inc.

Back to Newsroom

By Reuters

June 24, 20269:04 PM UTCUpdated 45 mins ago

Exxon Mobil logo and stock graph are seen through a magnifier displayed in this illustration taken September 4, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

CompaniesWASHINGTON, June 24 (Reuters) - U.S. ​President Donald ‌Trump said ​on ​Wednesday that Exxon ⁠Mobil (XOM.N), opens new tab ​and Chevron (CVX.N), opens new tab ​were among companies ​being ​probed as a ‌part ⁠of a surge in ​gas ​prices.

The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.

Reporting ⁠by ​Humeyra Pamuk ​and ⁠Kanishka Singh ⁠in ​Washington; ​Editing by ​Daphne Psaledakis

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Carnival Corp (NYSE:CCL)’s reduced fiscal 2026 guidance reflects near-term pressures rather than a change in its longer-term trajectory, according to Jefferies analysts, who reiterated a ‘Buy’ rating and maintained a $35 price target on the cruise operator's shares.

Shares of Carnival traded hands at about $29 on Wednesday afternoon, down about 5% this year.

Jefferies believes that Carnival's trimmed yield outlook is unlikely to derail what it views as a multi-year improvement story driven by margin expansion and more than $9 billion in free cash flow generation expected between fiscal 2026 and 2027.

The firm wrote that the level of cash generation should support organic growth investments, debt reduction and shareholder returns.

The analysts also noted that Carnival has exceeded its guidance for net yields, adjusted EBITDA and adjusted earnings per share in every quarter since the first quarter of 2025, suggesting the company's latest outlook could prove conservative.

Carnival lowered its fiscal 2026 net yield growth forecast to 3.2% from 4.1% previously. The company now expects adjusted EBITDA of about $7.11 billion, down slightly from its prior estimate of $7.19 billion, while adjusted earnings per share are projected at $2.22, compared with earlier guidance of $2.21.

For the third quarter of fiscal 2026, Carnival expects net yields to rise 1.3% year over year and adjusted EBITDA of $2.88 billion, both below Jefferies' prior estimates and Wall Street expectations.

According to Jefferies, management said demand was uneven during the second quarter because of the conflict involving Iran, though booking trends improved in June. Carnival also reported continued efficiencies in both fuel and non-fuel costs.

The company said refurbishment work on ships within its AIDA Cruises brand is progressing as planned, with a similar program expected to be extended to Holland America Line in the second half of 2027.

Jefferies noted that Carnival remains confident it can continue lowering leverage while investing in growth initiatives and returning capital to shareholders. The firm estimates the company could deliver roughly $3.5 billion in capital returns during the second half of fiscal 2026 and fiscal 2027 while reducing leverage to 2.9 times by the end of fiscal 2027.

Jefferies modestly lowered its revenue forecasts to reflect weaker yield assumptions but raised its adjusted EBITDA estimates to account for lower fuel and operating costs. The brokerage now projects fiscal 2026 revenue of $27.6 billion and adjusted EBITDA of $7.17 billion, compared with previous estimates of $27.9 billion and $7.05 billion, respectively.

Store

SubscribeSign In

My Subscriptions

Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center

My Stock Lists

Email Preferences

Help & Support

Sign Out

Search stocks or keywords

Sections

My IBD

MARKET TREND

STOCK LISTS

STOCK RESEARCH

NEWSECONOMY

VIDEOS & PODCASTS

HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products

Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live

Recently Searched

Chip Equipment Maker KLA Hits Record High, Leads 16 Stars Onto Best Stock Lists

AI Stock Market Leaders Thumped As SpaceX Takes Traders On Wild Ride; Three Strong Sell Rules To Use Now

Google-Parent Alphabet To Join Dow Jones Industrial Average, Replacing Verizon Honeywell's (HON) aerospace spinoff will be added to the S&P 500 index next week, while IES Holdings (IESC), a data center electric power provider, is going into the Midcap S&P 400. Both stocks rallied. Honeywell Aerospace (HONEV) will be officially in the S&P 500 at the start of trading on Monday, S&P Dow Jones Indices announced late Tuesday. The company…

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

-

SAN FRANCISCO--(BUSINESS WIRE)--Wells Fargo & Company (NYSE: WFC) today announced that it has completed the Federal Reserve’s 2026 supervisory stress test process. As previously announced by the Federal Reserve, this year’s stress test results do not impact bank capital requirements, and Wells Fargo’s stress capital buffer (SCB) remains at 2.5%.

The Company also announced that it expects to increase its third quarter 2026 common stock dividend by 11% to $0.50 per share from $0.45 per share, subject to approval by the Company’s Board of Directors at its regularly scheduled meeting in July. Additionally, the Company has capacity to continue repurchasing common stock, which will be routinely assessed as part of the Company’s internal capital adequacy framework that considers current market conditions, regulatory capital requirements, and other risk factors.

About Wells Fargo

Wells Fargo & Company (NYSE: WFC) is a leading financial services company that has approximately $2.2 trillion in assets. We provide a diversified set of banking, investment and mortgage products and services, as well as consumer and commercial finance, through our four reportable operating segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth & Investment Management. Wells Fargo ranked No. 33 on Fortune’s 2025 rankings of America’s largest corporations. News, insights, and perspectives from Wells Fargo are also available at Wells Fargo Stories.

Additional information may be found at www.wellsfargo.com

LinkedIn: https://www.linkedin.com/company/wellsfargo

Cautionary Statement About Forward-Looking Statements

This news release contains forward-looking statements about our future regulatory capital levels and possible future capital actions, including common stock dividends and repurchases. Because forward-looking statements are based on our current expectations and assumptions regarding the future, they are subject to inherent risks and uncertainties. Do not unduly rely on forward-looking statements as actual results could differ materially from expectations. Forward-looking statements speak only as of the date made, and we do not undertake to update them to reflect changes or events that occur after that date. Actual capital levels and capital actions may vary materially from expectations due to a number of factors, including those described in our reports filed with the Securities and Exchange Commission and available on its website at www.sec.gov. The amount and timing of any future common stock dividends or repurchases will depend on the earnings, cash requirements and financial condition of the Company, the impact to our balance sheet of expected customer activity, our capital requirements and long-term targeted capital structure, the results of supervisory stress tests, market conditions (including the trading price of our stock), regulatory and legal considerations, including regulatory requirements under the Federal Reserve Board’s capital plan rule, and other factors deemed relevant by the Company, and may be subject to regulatory approval or conditions.

News Release Category: WF-CFH

More News From Wells Fargo & Company

Back to Newsroom

Target: Managing Cyclical Revenue TrendsTarget (TGT +5.13%) primarily generates its revenue by selling a diverse mix of groceries, apparel, home decor, and general merchandise through its nationwide network of physical stores and its digital storefronts.

It recently appointed a new chief global supply chain officer and raised its quarterly dividend, while reporting a 3% net income margin for the quarter ended May 2, 2026.

Costco: Steady Growth Through Membership WarehousesCostco (COST +0.32%) operates global membership-based retail warehouses that offer customers bulk groceries, consumer electronics, and apparel, alongside ancillary services such as pharmacies, food courts, and gas stations.

It recently rolled out membership card entrance scanners nationwide and expanded its warehouse footprint, while posting a 13% gross margin for the quarter ended May 10, 2026.

Why Revenue Matters for Retail InvestorsRevenue here refers to the total amount of money a business brings in before deducting any operational expenses. It serves as a critical starting point for investors to understand the overall size, scale, and growth trajectory of a retail business.

Quarterly Revenue for Target and CostcoQuarter (Period End)Target RevenueCostco RevenueQ3 2024$25.5 billion (period ended Aug. 2024)$79.7 billion (period ended Sept. 2024)Q4 2024$25.7 billion (period ended Nov. 2024)$62.2 billion (period ended Nov. 2024)Q1 2025$30.9 billion (period ended Feb. 2025)$63.7 billion (period ended Feb. 2025)Q2 2025$23.8 billion (period ended May 2025)$63.2 billion (period ended May 2025)Q3 2025$25.2 billion (period ended Aug. 2025)$86.2 billion (period ended Aug. 2025)Q4 2025$25.3 billion (period ended Nov. 2025)$67.3 billion (period ended Nov. 2025)Q1 2026$30.5 billion (period ended Jan. 2026)$69.6 billion (period ended Feb. 2026)Q2 2026$25.4 billion (period ended May 2026)$70.5 billion (period ended May 2026)Data source: Company filings. Data as of June 23, 2026.

Foolish TakeExamining the revenue trends for Target and Costco reveal insightful information helpful to evaluating investments in these retail giants. Target’s sales spikes in the first quarter are because its fiscal Q1 spans the key holiday shopping season. Retailers typically see their largest sales during that time of year.

Costco experiences annual spikes in its fiscal third quarter, during the summer months, because it is a different kind of retailer from Target. It sells products in bulk, and during the summer, customers buy food for barbecues and purchase pricey items such as outdoor furniture. Consumers typically do not buy gifts in bulk during the holiday period.

Costco’s quarterly revenue is substantially higher than Target’s as a result not only of its bulk sales, but also to membership fees that Target lacks. These fees added $1.4 billion to Costco’s top line in its fiscal third quarter ended May 10.

As their revenue trends show, Target and Costco may both operate in the retail category, but their business models differ enough to make meaningful impacts on their income.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy or in combination with Keytruda® (pembrolizumab) or Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-mph) for patients whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.

“For people living with mTNBC, the first treatment choice can be pivotal, as many patients may not have the opportunity to receive subsequent therapies,” said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and a principal investigator of the ASCENT-03 and ASCENT-04 studies. “This approval is heartening news for patients and the clinical community, and I believe offers a practice-changing first-line treatment option for all patients across PD-L1 status.”

The FDA approval is based on highly statistically significant and clinically meaningful progression-free survival (PFS) data from the Phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, where Trodelvy-based regimens significantly reduced the risk of disease progression or death in first-line mTNBC—by 38% as monotherapy versus chemotherapy in PD-L1 ineligible disease in ASCENT-03 and by 35% in combination with Keytruda versus Keytruda plus chemotherapy in PD-L1+ disease in ASCENT-04.

Across ASCENT-03 and ASCENT-04, Trodelvy-based regimens delivered markedly more durable responses, with median duration of response of 12.2 versus 7.2 months with chemotherapy in ASCENT-03 and 16.5 versus 9.2 months for Trodelvy plus Keytruda versus Keytruda plus chemotherapy in ASCENT-04 by blinded independent central review.

“For patients with metastatic TNBC, a new first-line treatment option offers optimism to a community with historically few choices,” said Ricki Fairley, Co-Founder and CEO of TOUCH, The Black Breast Cancer Alliance. “TNBC disproportionately affects younger women - many in the prime of their lives - and often leads to poorer outcomes. Because so many patients may never receive subsequent lines of therapy, the ability to start with a promising option like Trodelvy with or without Keytruda is critical. We have sought additional alternatives to chemotherapy-containing regimens in the first-line metastatic setting since TNBC was classified as a disease more than 20 years ago. As such, this approval represents meaningful progress for the families impacted by this disease.”

“The FDA’s approval of Trodelvy provides a new standard of care for the most aggressive form of breast cancer,” said Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences. “For more than twenty years, patients with mTNBC have had limited choices in first-line treatment. Building on its impact in second-line mTNBC, Trodelvy now offers patients a powerful new backbone therapy option in the first-line setting.”

Based on the ASCENT-03 and ASCENT-04 positive study results, the National Comprehensive Cancer Network® (NCCN®) recommends Trodelvy with or without Keytruda as a category 1 preferred first-line treatment option for people with mTNBC across PD-L1 status in the NCCN Guidelines®i. Trodelvy also has a category 1 recommendation in second-line mTNBC and in pre-treated HR+/HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) metastatic breast cancer (mBC).

Healthcare professionals have well-established experience with Trodelvy, with more than 75,000 breast cancer patients treated across more than 60 countries over the past six years. It remains the only Trop-2-directed ADC to demonstrate meaningful overall survival benefits in both second-line or later metastatic TNBC and pre-treated HR+/HER2- mBC. It is also the only ADC with four positive Phase 3 trials in HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) mBC.

Please see below for the U.S. Indication and Important Safety Information for Trodelvy, including Boxed Warning.

KEYTRUDA® and KEYTRUDA QLEX™ are trademark(s) of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About Triple-Negative Breast Cancer

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat, accounting for approximately 15% of all breast cancers. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. TNBC cells do not have estrogen and progesterone receptors and have limited HER2 expression. Due to the nature of TNBC, treatment options are extremely limited compared with other breast cancer types. TNBC has a higher chance of recurrence and metastases than other breast cancer types. The average time to metastatic recurrence for TNBC is approximately 2.6 years compared with 5 years for other breast cancers, and the relative five-year survival rate is much lower. Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of mBC.

First-line metastatic TNBC has seen limited new approvals in recent years and additional options are urgently needed. Over 50% of patients do not receive treatment beyond first-line, reinforcing the urgent need for new options to help improve patient outcomes. Breast cancers expressing PD-L1 are overall more aggressive and associated with reduced survival time.

About Trodelvy

Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and lung cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the tumor microenvironment through a bystander effect.

Trodelvy is currently approved in more than 60 countries for second-line or later metastatic triple-negative breast cancer (TNBC) and in more than 50 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer (mBC). Global regulatory submissions for the approval of Trodelvy based on ASCENT-03 and ASCENT-04 are underway.

Trodelvy is currently being evaluated in multiple ongoing Phase 3 trials across a range of tumor types with high Trop-2 expression. These studies with Trodelvy, both in monotherapy and in combination with pembrolizumab, involve earlier lines of treatment for TNBC and HR+/HER2- breast cancer—including in curative settings—as well as in lung and gynecologic cancers, where previous proof-of-concept studies have demonstrated clinical activity.

INDICATIONS

TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2–directed antibody and topoisomerase inhibitor conjugate indicated in adult patients:

Locally Advanced or Metastatic Triple-Negative Breast Cancer

First Line

As a single agent for the first-line treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of unresectable locally advanced or mTNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥10)] as determined by an FDA-authorized test Second Line or Later

For the treatment of unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer

For the treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. IMPORTANT SAFETY INFORMATION

BOXED WARNING: NEUTROPENIA AND DIARRHEA

TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤Grade 1 and reduce subsequent doses. CONTRAINDICATIONS

Severe hypersensitivity reaction to TRODELVY. WARNINGS AND PRECAUTIONS

Neutropenia: Severe, life-threatening, or fatal neutropenia can occur as early as the first cycle of treatment and may require dose modification. Neutropenia occurred in 64% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 48% of patients. Febrile neutropenia occurred in 6%. Neutropenic colitis occurred in 1.4%. Primary prophylaxis with G-CSF is recommended starting in the first cycle of treatment in all patients at increased risk of febrile neutropenia, including older patients, patients with previous neutropenia, poor performance status, organ dysfunction, or multiple comorbidities. Monitor absolute neutrophil count (ANC) during treatment. Withhold TRODELVY for ANC below 1500/mm3 on Day 1 of any cycle or below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever. Treat neutropenia with G-CSF and administer prophylaxis in subsequent cycles as clinically indicated or indicated in Table 2 of USPI.

Diarrhea: Diarrhea occurred in 62% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 10% of patients. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.6% of all patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to ≤Grade 1. At onset, evaluate for infectious causes and, if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (eg, fluid and electrolyte replacement) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (eg, atropine) for subsequent treatments.

Hypersensitivity and Infusion-Related Reactions: TRODELVY can cause serious hypersensitivity reactions, including life-threatening anaphylactic reactions. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, and skin reactions. Hypersensitivity reactions occurred in 28% of patients with 13% occurring within 24 hours of dosage. Grade 3-4 hypersensitivity occurred in 1.5% of patients with 0.4% of these occurring within 24 hours of dosage. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.4%. The incidence of anaphylactic reaction was <0.1%. Pre-infusion medication is recommended. Have medications and emergency equipment to treat such reactions available for immediate use. Closely monitor patients for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Permanently discontinue TRODELVY for Grade 4 infusion-related reactions.

Nausea and Vomiting: TRODELVY is emetogenic and can cause severe nausea and vomiting. Nausea occurred in 63% of all patients treated with TRODELVY, and Grade 3-4 nausea occurred in 3% of these patients. Vomiting occurred in 33% of patients, and Grade 3-4 vomiting occurred in 2% of these patients. Premedicate with a two- or three-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist, as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting. Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to ≤Grade 1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Increased Risk of Adverse Reactions in Patients With Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with TRODELVY. The incidence of Grade 3-4 neutropenia was 57% in patients homozygous for the UGT1A1*28 allele, 48% in patients heterozygous for the UGT1A1*28 allele, and 41% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 17% in patients homozygous for the UGT1A1*28 allele, 9% in patients heterozygous for the UGT1A1*28 allele, and 8% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration, and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.

Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.

ADVERSE REACTIONS

In the pooled safety population of TRODELVY as a single agent, the most common (≥25%) adverse reactions, including laboratory abnormalities, were decreased leukocyte count (83%), decreased neutrophil count (77%), decreased hemoglobin (71%), nausea (63%), diarrhea (62%), decreased lymphocyte count (60%), fatigue (59%), alopecia (47%), increased glucose (40%), constipation (37%), vomiting (33%), decreased albumin (32%), increased alkaline phosphatase (30%), decreased appetite (28%), abdominal pain (27%), decreased creatinine clearance (27%), decreased magnesium and potassium (26% each).

In the safety population of TRODELVY in combination with pembrolizumab, the most common (≥25%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count and hemoglobin (86% each), decreased leukocyte count (84%), diarrhea (72%), nausea (68%), decreased lymphocyte count (61%), fatigue (58%), alopecia (52%), increased alkaline phosphatase and glucose (50% each), increased alanine aminotransferase (47%), constipation (41%), increased aspartate aminotransferase (40%), rash (37%), decreased potassium (35%), increased lactate dehydrogenase (34%), vomiting (29%), abdominal pain, headache, and increased eosinophils (26% each), and decreased albumin (25%).

In the ASCENT-03 study (single agent in previously untreated, unresectable locally advanced or mTNBC), the most common adverse reactions (incidence ≥25%) were nausea, diarrhea, alopecia, fatigue, constipation, and vomiting. The most frequent serious adverse reactions (SAR) (>2%) were diarrhea, febrile neutropenia, and neutropenia (3.6% each), and pneumonia (2.9%). SAR occurred in 26% of patients, and 3.6% permanently discontinued TRODELVY due to adverse reactions. Fatal adverse reactions occurred in 2.5% of patients and included sepsis (1.1%), and acute respiratory failure, neutropenic colitis, pneumonia, and septic shock (0.4% each). The most common Grade 3-4 lab abnormalities (incidence ≥25%) were decreased neutrophils and leukocytes.

In the ASCENT-04 study (in combination with pembrolizumab in previously untreated, unresectable locally advanced or mTNBC whose tumors express PD-L1), the most common adverse reactions (incidence ≥25%) were diarrhea, nausea, fatigue, alopecia, constipation, rash, vomiting, abdominal pain, and headache. The most frequent SAR (≥2%) were febrile neutropenia (7%), neutropenia (6%), diarrhea (5%), and fatigue and pneumonia (2.3% each). SAR occurred in 38% of patients, and 7% permanently discontinued TRODELVY due to adverse reactions. Fatal adverse reactions occurred in 3.2% of patients and included death (unknown cause) (0.9%) and completed suicide, neutropenic sepsis, sepsis, pneumonia, and pulmonary embolism (0.5% each). The most common Grade 3-4 lab abnormalities (incidence ≥25%) were decreased neutrophils and leukocytes.

In the ASCENT study (previously treated locally advanced or mTNBC), the most common adverse reactions (incidence ≥25%) were fatigue, diarrhea, nausea, alopecia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent SAR (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR occurred in 27% of patients, and 5% permanently discontinued TRODELVY due to adverse reactions. Fatal adverse reactions occurred in 1.2% of patients and included respiratory failure (0.8%) and pneumonia (0.4%). The most common Grade 3-4 lab abnormalities (incidence ≥25%) were decreased neutrophils, leukocytes, and lymphocytes.

In the TROPiCS-02 study (locally advanced or metastatic HR+/HER2– breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent SAR (>1%) were diarrhea (5%), febrile neutropenia (4.1%), neutropenia (3%), abdominal pain (2.2%), neutropenic colitis and vomiting (1.9% each), and colitis and pneumonia (1.5% each). SAR occurred in 28% of patients, and 6% permanently discontinued TRODELVY due to adverse reactions. Fatal adverse reactions occurred in 2.2% of patients and included arrhythmia, COVID-19 pneumonia, pneumonia, nervous system disorder, pulmonary embolism, and septic shock (0.4% each). The most common Grade 3-4 lab abnormalities (incidence ≥25%) were decreased neutrophils and leukocytes.

DRUG INTERACTIONS

UGT1A1 Inhibitors: Avoid administering UGT1A1 inhibitors with TRODELVY. SN-38 is a UGT1A1 substrate. Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38.

UGT1A1 Inducers: Avoid administering UGT1A1 inducers with TRODELVY. SN-38 is a UGT1A1 substrate. Concomitant administration of TRODELVY with inducers of UGT1A1 may reduce exposure to SN-38.

Please see full Prescribing Information, including BOXED WARNING.

About Gilead and Kite Oncology

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials or studies, including those involving sacituzumab govitecan-hziy (such as ASCENT-03 and ASCENT-04); uncertainties relating to regulatory applications and related filing and approval timelines, including potential applications for programs and/or indications currently under evaluation, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; the risk that physicians and patients may not see advantages of Trodelvy for first-line mTNBC and may therefore be reluctant to prescribe the products; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

U.S. Prescribing Information for Trodelvy, including BOXED WARNING, is available at www.gilead.com.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

i Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 4.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed June 16, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

More News From Gilead Sciences, Inc.

© vzphotos / iStock Editorial via Getty Images

I hit the buy button on AbbVie (NYSE:ABBV | ABBV Price Prediction) again last week, and I will hit it again the next time June’s macro noise hands me a discount. While short-term traders chase headlines around sticky 4.2% inflation and a softening jobs picture, I keep adding shares of a cash machine that does not care which way the next data release breaks.

The thesis is straightforward. AbbVie has rebuilt itself around two next-generation immunology drugs that are growing fast enough to bury the old Humira narrative, and the market is finally paying for that work. Skyrizi posted $4.48 billion in Q1 2026 revenue, up 30.9% year over year. Rinvoq added $2.12 billion, up 23.3%. The full immunology franchise grew 16.4% to $7.29 billion, even with Humira down 38.6% against biosimilars. That is the replacement story playing out on the income statement in real time.

Then there is the dividend, which is the real reason I keep showing up. The quarterly payout sits at $1.73, after a 5.5% increase in January 2026. Stretch back ten years and the quarterly check has climbed from $0.57 in 2016 to $1.73 today, layered on top of AbbVie’s 52-year history of consecutive dividend increases dating back to its Abbott roots. The yield has compressed to roughly 2.95% because shares ran 31.95% over the past year and 147% over five years. I treat that compression as confirmation the thesis is working.

The economics behind the payout look just as durable. AbbVie carries a 70.2% gross margin and a 32.85% operating margin, and Q1 2026 revenue came in at $15.00 billion, up 12.4% year over year and beating consensus by 1.93%. Management used the strength to raise full-year adjusted EPS guidance to $14.08 to $14.28. CEO Robert A. Michael told investors, “AbbVie’s key growth drivers continue to deliver strong performance and support our enhanced full-year outlook.” Against that guide, the forward earnings multiple of 16 is hardly demanding for a business compounding revenue at double digits with a beta of 0.309.

The real risk is the patent cliff that never quite goes away. Humira keeps bleeding, Imbruvica fell 24.7% in the quarter, and some analysts are already flagging concerns about growth past 2028. Negative shareholders’ equity from years of buybacks and acquisitions sits on the balance sheet as a reminder that this is a leveraged compounder. I have weighed all of it. The reason I keep buying anyway is that Skyrizi and Rinvoq are tracking ahead of the original replacement timeline, neuroscience grew 26.0% with Qulipta up 53.6%, and the pipeline keeps producing wins like the FDA approval of Venclexta plus acalabrutinib for previously untreated CLL.

Add in a $100 billion U.S. R&D and capex commitment over the next decade, a $1.4 billion manufacturing campus going up in Durham, and a 62.15% return on equity, and the picture is a defensive compounder priced like an ordinary drug stock. June’s jobs wobble does not change any of that. It just gives me cheaper share prices on the way to a bigger quarterly check, and that is the only confession of conviction I owe.

Wedbush analyst Daniel Ives kept a bullish view on Palantir Technologies PLTR on June 24, saying the stock could rise sharply over the next 12 months.

Ives repeated a Buy rating and set a price target of about $230 for Palantir, implying upside of nearly 100% from the shares' recent level around $114. Palantir's push into enterprise artificial intelligence remains the main driver behind his call.

The analyst also pointed to Palantir's partnership with Zeta Global Holdings Corp. as a key support for the case. Palantir said the deal could generate more than $100 million in revenue for Zeta over several years, while Ives said the market may still be underestimating the company's role in enterprise AI.

Palantir Chief Executive Alex Karp has also argued that corporate clients want AI tools that solve operational problems, not just generate tokens. Palantir shares were down more than 30% year to date

Characteristics and Risks of Standardized Options: https://bit.ly/2v9tH6D. Lots of visibility into the AI demand story will be seen in Micron's (MU) earnings, says Kevin Hincks.

Micron's revenue more than quadrupled in the fiscal third quarter, the company said on Wednesday, as the memory maker continued to benefit from soaring demand tied to the artificial intelligence boom. The stock rose over 16% at one point in extended trading.

Here's how the memory maker did versus LSEG consensus estimates:

Revenue: $41.46 billion versus $35.84 billion estimatedEPS: $25.11, adjusted, versus $20.78 estimatedRevenue increased from $9.3 billion a year earlier, Micron said in a statement. For the current quarter, the company said it expects revenue of about $50 billion, up from $11.3 billion a year earlier. Analysts were looking for a revenue forecast of $43.58 billion, according to LSEG.

Memory prices have skyrocketed in the last couple years as AI chips eat up all the production capacity of the small crop of vendors. With data center demand increasing by the day, prices are also rising for memory used in smartphones, laptops and other gadgets.

"Our customers are recognizing that supply shortages in memory and storage will take considerable time to improve, even as we expect industry supply to improve gradually in 2028," Micron CEO Sanjay Mehrotra said on a call with analysts.

That's turned Micron into a Wall Street darling as its technology is essential for chips made by Nvidia and Google, as well as the servers that house those companies' processors. Micron's stock price is up roughly 700% over the past year, lifting the company's market cap past $1 trillion.

Micron said on Wednesday that it has signed 16 long-term agreements with customers such as data center operators and automakers that lock in sales for a period of three to five years.

"When completed, we expect approximately half or more of our company revenue to be under these" strategic customer agreements, Mehrotra said. He added that they were structured with binding agreements to purchase volumes of Micron's chips.

Micron said it expected financial commitments of $22 billion from the 16 long-term agreements.

"This is good for Micron," CFO Mark Murphy told analysts. "We get visibility on our demand, it's committed volume that we can be confident about making our investments."

Micron's gross margin, the profit left after accounting for the cost of goods sold, jumped to 84.9% in the third quarter from 74.9% in the prior period and 39% a year earlier. Micron's margins topped analyst estimates.

Net income during the quarter was $28.24 billion, or $24.46 per share, versus $1.89 billion, or $1.68 per share in the year-ago period.

While all four of Micron's business units saw revenue multiply, the most explosive growth was in the core data center business, where sales climbed more than sevenfold to $11.5 billion from $1.53 billion in the same period a year ago. In addition to memory, Micron also recorded over $5 billion in data center solid state drive revenue, the company said in a presentation.

Cloud memory was up over 300% to $13.77 billion.

Sales for memory for devices also grew as prices rose. The company's mobile and client business unit saw revenue grow over 250% to $11.52 billion, and even memory for automotive and embedded applications more than quadrupled to $4.63 billion in sales.

The company said shareholders will receive a 15 cent dividend in July.

watch now

Micron's (MU) posted a significant beat on EPS, revenue, margins, and guidance — all showing signs that AI memory demand isn't slowing down. Marley Kayden, Sam Vadas, and Alex Coffey offer more insight into all of the key metrics surrounding Micron's report immediately following its release as shares rally after hours.

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Greifeld, Carol Massar and Tim Stenovec. -------- More on Bloomberg Television and Markets Like this video?

Micron Technology Inc (NASDAQ:MU) shares rose about 14% in extended trading on Wednesday after the memory chipmaker reported fiscal third quarter results that exceeded Wall Street expectations and issued stronger-than-anticipated guidance for the current quarter.

The company posted non-GAAP earnings of $25.11 per share on revenue of $41.46 billion for the quarter ended May 28, surpassing analyst estimates of $20.39 per share and $35.1 billion in revenue, respectively.

Revenue more than doubled from $9.3 billion a year earlier and increased from $23.86 billion in the previous quarter. GAAP net income climbed to $28.24 billion, or $24.67 per diluted share, from $1.89 billion, or $1.68 per share, in the year-ago period.

Operating cash flow totaled $25.39 billion, compared with $11.9 billion in the prior quarter and $4.61 billion a year earlier.

Adjusted free cash flow reached $18.3 billion, while capital expenditures were $7.1 billion. Micron ended the quarter with $30.2 billion in cash, marketable investments and restricted cash.

"Micron's record fiscal Q3 financial results and even stronger outlook for Q4 reflect the strategic value of memory in the AI era," Micron CEO Sanjay Mehrotra said in a statement.

"Micron is investing at record levels in technology, products and supply to address our customers' rapidly growing demand. We believe our multi-year Strategic Customer Agreements will significantly enhance the durability and predictability of Micron's strong financial performance."

The company highlighted what it described as transformational Strategic Customer Agreements, which it said are expected to improve the predictability of its business over multiple years.

Micron's Cloud Memory Business Unit generated revenue of $13.77 billion during the quarter, while the Core Data Center Business Unit contributed $11.52 billion.

The Mobile and Client Business Unit recorded revenue of $11.52 billion, and the Automotive and Embedded Business Unit reported $4.63 billion.

For the fiscal fourth quarter, Micron forecast revenue of approximately $50 billion, plus or minus $1 billion, and non-GAAP earnings of about $31 per share, plus or minus $1.00. The company expects non-GAAP gross margin of roughly 86%.

Micron also declared a quarterly dividend of $0.15 per share, payable on July 21 to shareholders of record as of July 6.

ToplineMicron shares rocketed Wednesday after the chipmaker reported the most profitable quarter in its history, further cementing its role as a beneficiary of the artificial intelligence infrastructure boom.

Micron shares rocketed Wednesday.

Photo by Jonathan Raa/NurPhoto via Getty Images

Key FactsMicron shares briefly jumped more than 15% in extended trading Wednesday after it closed the day down a fraction of a percent.

Micron reported third-quarter revenue of $41.4 billion, up from $9.3 billion in the same period a year ago, according to a filing.

Adjusted diluted earnings per share came in at $25.11, a massive jump from the $1.91 posted in the year-ago quarter, while net income reached $28.24 billion.

Micron set its fourth quarter revenue guidance to $50 billion alongside adjusted diluted earnings per share of $31.00.

Bulls behind Micron’s stock will likely point to the earnings report as proof the company’s earnings stream will prove more durable than bears fear, according to a note from market insights firm Vital Knowledge, which noted supply and demand conditions for Micron will remain tight for at least the next one and a half years.

ContraBears are likely to remain concerned about how Micron can keep up its supply for extreme AI demand, Vital Knowledge’s note added. Micron’s High Bandwidth Memory chips, which allow AI processors to work faster, are completely sold out, as the company has reportedly allocated all of its chip supply for 2026 to commitments with AI data centers. Vital Knowledge also identified management’s expectation for higher capital expenditure ($10 billion in fiscal quarter four) as a potential red flag.

Key BackgroundMicron’s stock has been highly volatile recently. A global chip selloff Tuesday pushed the company’s shares down 13%, erasing two days’ worth of gains. JPMorgan analysts said Tuesday the selloff may have been provoked by anxiety around Micron’s earnings, which are usually seen as a bellwether for AI demand. However, Wednesday’s after-hours surge brought shares from about the $1,050 mark to around $1,175. While concerns have mounted over whether Micron’s stock is driven by momentum trading or fundamentals, the chipmaker has traded up more than 260% since the start of the year amid the AI boom and its demand for Micron products.

Further ReadingMicron Tumbles 13% As South Korean ETF Warning Fuels Chip Sell-Off (Forbes)

The S&P 500 (^GSPC 0.10%) slipped 0.10% to 7,358.22, the Nasdaq Composite (^IXIC 0.43%) fell 0.43% to 25,476.63 on semiconductor volatility, while the Dow Jones Industrial Average (^DJI +0.35%) gained 0.35% to 51,848.90 as it welcomed new components.

Gold futures fell 3.20% to $4,016.82, and the 10-Year Treasury yield slipped 0.09% to 4.40% as of U.S. market close. Sector performance was mixed, as healthcare stocks gained 1.17% while technology dipped 0.69%.

Today's biggest movesAmazon.com shares edged up slightly on Prime Day optimism, but other tech giants such as Nvidia and Apple fell. Today’s big story was Micron Technology, which reported earnings after the close. The stock finished down 0.31% but soared over 13% in after-hours trading following a beat on analyst estimates and strong guidance.

Chipmaker Cerebras Systems crashed following its first earnings report as a public company. Wendy's jumped 26% today after the stock went viral. Hertz tumbled over 40% after announcing a $100 million stock offering and lower guidance.

What this means for investorsMajor U.S. indexes were little changed today, as falling oil prices helped improve sentiment and tech stocks stemmed recent losses. Micron’s strong results may go some way to reassure investors worried about high artificial intelligence (AI) spending.

If you are unsure about how to navigate the current markets, a mid-year note from JPMorgan may help. Analysts highlighted earnings resilience as they increased their end-of-year S&P 500 price target from 7,600 to 7,800 — a 6% increase on today’s close.

However, with anticipated rate hikes and high levels of speculative trading, the report warns that it won’t be plain sailing, noting the strong possibility of a reversal or flash crash. In that scenario, a stock market crash could be an opportunity to pick up quality stocks with strong long-term potential.

JPMorgan Chase is an advertising partner of Motley Fool Money. Emma Newbery has positions in Amazon, Apple, and Nvidia. The Motley Fool has positions in and recommends Amazon, Apple, JPMorgan Chase, Micron Technology, and Nvidia. The Motley Fool has a disclosure policy.

Key Takeaways South Korean memory chip giant SK Hynix said it's looking to list on the Nasdaq as soon as July 10.The Nvidia partner's stock has helped send Korea- and chip-themed funds higher this year as AI demand drives up sales. Get personalized, AI-powered answers built on 27+ years of trusted expertise.

One of the world's hottest names in memory could be coming to the U.S. stock market soon.

South Korean memory chip giant SK Hynix, the Nvidia (NVDA) partner and Micron (MU) rival that's played a key role in driving Korea- and chip-themed funds higher this year, said in a regulatory filing Wednesday that it's looking to list on the Nasdaq as soon as July 10.1 The company plans to list on the Nasdaq with the ticker symbol "SKHY," the filing said.

To get there, the company said it plans to issue 17.79 million new shares; they will trade in the U.S. as American depositary receipts. The deal will raise 45.45 trillion won ($29.65 billion), according to the filing. Its shares listed in Korea added 1% yesterday; they have roughly tripled in value since the year began and are up some 800% over the past 12 months.

Why This Matters to Investors The move would make it easier for American investors to get direct exposure and widen SK Hynix's investor base, which could also boost the shares.

A memory shortage driven by booming demand for AI hardware has led to soaring profits for major memory chipmakers such as SK Hynix, which holds nearly 60% of the global market for high-bandwidth memory, according to a report earlier this month from Counterpoint Research.2 SK Hynix in April posted record first-quarter sales to the tune of 52.58 trillion Korean won, or around $34.09 billion.3

Its American rival Micron, which reported earnings after the closing bell today, turned in revenue of $41.46 billion for the quarter ended in May, well ahead of estimates compiled by Visible Alpha.45 Micron's stock, which set a record high on Monday, is up some 260% for the year so far and 700% over the past 12 months.

Exchange-traded funds heavily concentrated in SK Hynix, along with Micron, have seen big gains this year as investors clamored for exposure to memory as "pick-and-shovel" plays for the AI boom.

The Roundhill Memory ETF (DRAM)—comprised nearly 75% of SK Hynix, Samsung, and Micron—has soared more than 150% from where it opened at the beginning of April, making it the best-performing non-leveraged U.S. equity ETF this year, according to TradingView data.

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 24, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) ("Zillow" or the "Company"), if they purchased or otherwise acquired Zillow Class A or Class C common stock between February 11, 2025 and May 7, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Washington.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=hIyQUNEoCGc

What You May Do

If you purchased shares of Zillow as described above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-zg-z/?prs=nf to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 10, 2026.

CLICK HERE for more information

About the Lawsuit

Zillow and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) Zillow's agreement with Redfin was not a "partnership," but rather an acquisition of Redfin's business; (ii) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (iii) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (iv) as a result, Defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

The case is Breidert v. Zillow Group, Inc., et al., 26-cv-02016.

To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors, in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

For More Information about the case, Click HERE

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302749

Source: Kahn Swick & Foti, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

-

NEW YORK--(BUSINESS WIRE)--Morgan Stanley (NYSE: MS) announced that it will increase its quarterly common stock dividend to $1.15 per share from the current $1.00 per share, beginning with the common stock dividend expected to be declared by the Firm’s Board of Directors in the third quarter of 2026.

In addition, the Firm’s Board of Directors reauthorized a multi-year common equity share repurchase program of up to $20 billion, without a set expiration date, beginning in the third quarter of 2026. The share repurchases will be exercised from time to time at prices the Firm deems appropriate, subject to various considerations, including current market conditions, the Firm’s capital position and future economic and earnings outlook.

Ted Pick, Chairman and Chief Executive Officer of Morgan Stanley, said, “We have a globally scaled business that supports the Firm’s durable returns and strong capital position. Our financial strength gives us ongoing flexibility to invest in growth opportunities across the Integrated Firm while increasing the return of capital to shareholders.”

On June 24, 2026, the Board of Governors of the Federal Reserve System released its CCAR 2026 results which do not impact the Firm’s Stress Capital Buffer (SCB) requirement. On February 4, 2026, the Federal Reserve announced that it expects the Firm will continue to be subject to its current SCB requirement of 4.3% until October 1, 2027, at which time a new SCB requirement may apply based on the results of the supervisory stress test conducted in 2027. Together with other features of the regulatory capital framework, this SCB results in an aggregate U.S. Basel III Standardized Approach Common Equity Tier 1 (CET1) ratio of 11.8%. The Firm’s U.S. Basel III Standardized Approach CET1 ratio was 15.1% as of March 31, 2026.

Morgan Stanley is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.

Forward-Looking Statements

This Release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they are made, which reflect management’s current estimates, projections, expectations, assumptions, interpretations or beliefs of Morgan Stanley’s future results, regulatory capital levels and future capital actions, including common stock dividends and common equity share repurchases, and which are subject to risks and uncertainties that may cause actual results to differ materially. Morgan Stanley does not undertake to update the forward-looking statements to reflect the impact of circumstances or events that may arise after the date of forward-looking statements. For a discussion of additional risks and uncertainties that may affect the future results, regulatory capital levels and future capital actions of Morgan Stanley, please see “Forward-Looking Statements” preceding Part I, Item 1, “Competition” and “Supervision and Regulation” in Part I, Item 1, “Risk Factors” in Part I, Item 1A, “Legal Proceedings” in Part I, Item 3, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 and “Quantitative and Qualitative Disclosures about Risk” in Part II, Item 7A, in Morgan Stanley’s Annual Report on Form 10-K for the year ended December 31, 2025 and other items throughout the Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including any amendments thereto.

More News From Morgan Stanley

Back to Newsroom

watch now

The CEOs of Boeing, Lockheed Martin and Honeywell arrived at the White House on Wednesday for a meeting with President Donald Trump, as the administration presses major defense contractors to ramp up weapons production amid concerns about U.S. missile and munitions stockpiles.

The meeting comes after U.S. military operations in Iran and amid ongoing peace talks with Tehran, giving the White House added urgency to replenish key weapons systems and reassure allies that the U.S. defense industrial base can keep pace with demand.

The White House on Wednesday asked Congress for $87.6 billion in supplemental spending, primarily to pay for the Iran war. On Tuesday, the Senate adopted an Iran war powers resolution directing Trump to end U.S. hostilities with Tehran, a symbolic bipartisan rebuke that highlighted growing congressional scrutiny of the president's military strategy and peace talks.

Trump earlier this month invoked the Defense Production Act to accelerate weapons production, citing systemic constraints in the munitions base, including limited production capacity, fragile supply chains and long lead times.

But scaling weapons production is usually measured in years, not months, complicating the Trump administration's push for faster output.

The White House has also pushed contractors to prioritize existing Pentagon contracts, faster deliveries and American manufacturing capacity over shareholder payouts. And last week a key Senate committee approved a bill that would codify a January Trump executive order to require that defense contractors get Pentagon sign off to buy back shares or issue dividends. Defense contractors have opposed the mandate.

Wednesday's meeting follows a March White House gathering with executives from major defense firms, including Lockheed Martin, RTX, Boeing, Northrop Grumman, BAE Systems, Honeywell Aerospace and L3Harris.

The administration has been seeking to expand production of Patriot and THAAD interceptors, Tomahawk cruise missiles and AMRAAM air-to-air missiles, though industry executives have warned that major investments will require congressional funding.

Broadcom (AVGO +0.27%) has been on a blistering run in recent years, but those gains have been accompanied by significant volatility. The artificial intelligence (AI) chipmaker has gained 580% since the advent of AI in early 2023, but has fallen 10% or more on at least nine separate occasions and is currently 21% off its peak. Case in point: Broadcom stock crashed 41% in early 2025, so it isn't for the faint-hearted.

Uncertainty about the future of AI adoption has some investors sitting on the sidelines, but the evidence continues to mount that the company has a bright future.

Broadcom and OpenAI have joined forces to create an AI chip that the pair believes will be a game changer. The companies unveiled the custom-built processor, dubbed "Jalapeño," on Wednesday, marking OpenAI's first foray into physical silicon development.

Image source: The Motley Fool.

A spicy new AI processorThe new chip is the first step in OpenAI's long-term strategy to design computer chips and accessories that will underpin its evolving AI models. In a joint news release, Broadcom and OpenAI noted that they went back to the drawing board to design Jalapeño, which was "built from the ground up" and optimized for the unique demands of large language models (LLMs).

Jalapeño was designed specifically to be more efficient when working with ChatGPT and Codex, OpenAI's coding agent. It was also intended to work well with LLMs that the company develops in the future.

On an intriguing note, OpenAI revealed that the chip was designed with the help of its AI models. In an interview with CNBC, OpenAI president Greg Brockman said, "The degree to which our models have been able to accelerate [the chip development process] was very surprising to us."

While the chip's final performance testing isn't yet complete, early results suggest that Jalapeño’s performance per watt will be "substantially better" than current cutting-edge processors.

The breakthrough design focuses on reducing data movement across the chip and balancing the demands on compute, memory, and networking resources. In doing so, the processor achieves performance that is much closer to theoretical peak performance.

For example, one of the biggest drags on processing speed -- or latency -- is the need to move information around the chips. By minimizing data movement and reducing latency, OpenAI believes it will speed the next generation of AI inference -- the tasks for which AI models are designed.

Today's Change

(

0.27

%) $

1.02

Current Price

$

381.17

Brockman also said, "By designing more of the stack ourselves, we can serve more intelligence with greater efficiency and keep pushing advanced AI toward broader access." In essence, making AI more widely available.

Broadcom CEO Hock Tan noted that this was the first step in a "multi-generation roadmap." He went on to say that the collaboration represents a "fundamental commitment to scaling the physical infrastructure required for the next decade of AI.

What this means for Broadcom investorsBroadcom's biggest customers are among the tech elite, including such high-profile names as Alphabet, Meta Platforms, TikTok parent ByteDance, AI start-up Anthropic, and -- of course -- OpenAI. The company continues to expand its relationships with existing customers, which bodes well for the future.

Earlier this year, Tan said, "We have line of sight to achieve AI revenue from chips, just chips, in excess of $100 billion in 2027." For context, Broadcom's total revenue was roughly $64 billion in 2025, and its AI semiconductor revenue was just $10.8 billion in Q2, helping to underscore the magnitude of the growth yet to come.

Yet for all that opportunity, the stock is selling for 19 times next year's expected earnings. That's an attractive price for an industry leader driven by strong secular tailwinds.

That's why Broadcom is a buy.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© schulzhattingen / iStock Editorial via Getty Images

Air Products & Chemicals (NYSE:APD | APD Price Prediction) is a stock worth owning for decades because it sells an essential, contractually locked-in product into every corner of the global industrial economy and has raised its dividend for 44 consecutive years. For a retirement investor who has been whipsawed by thematic trades, this is the kind of position that historically rewards patience.

Pillar 1: A Business Structure That Cannot Be Dislodged Air Products supplies oxygen, nitrogen, hydrogen and helium to refineries, semiconductor fabs, hospitals and food processors. Its production facilities are typically built directly adjacent to customer plants or connected by dedicated pipeline, under multi-decade take-or-pay contracts. A customer cannot switch suppliers without risking factory shutdown, which is why the company’s on-site backlog keeps compounding regardless of who occupies the White House or what the 10-year yield is doing.

That durability is showing up in the numbers. Q2 FY2026 revenue rose 9% to $3.171 billion, adjusted EPS grew 19%, and operating margin expanded over 200 basis points to 23.7%. CEO Eduardo Menezes also announced a Samsung agreement to build, own and operate gas supply for an advanced Korean semiconductor fab, which he called “the largest investment we ever made in the electronics side”, and the company is supplying liquid hydrogen and helium to NASA’s Artemis program.

Pillar 2: Income You Can Set Your Calendar To The Q1 FY26 dividend was raised to $1.81 per quarter, the latest step in a streak that has taken the quarterly payout from roughly $0.17 in 1999 to $1.81 in 2026. The forward yield sits around 2.56% on a share price of $282.45, and operating cash flow has covered the dividend roughly 2x or better every year for a decade. The dividend has grown 134% over ten years while the underlying cash engine kept producing $3 billion to $3.6 billion of operating cash annually. That is the definition of a compounder.

Pillar 3: Built to Survive Cycles Industrial gas demand is non-discretionary. Refineries cannot stop buying hydrogen, hospitals cannot stop buying oxygen, and chip fabs cannot stop buying nitrogen. APD’s contracts include energy cost pass-throughs, its beta is just 0.747, and management is reducing capex to approximately $4 billion in fiscal 2026 from over $7 billion the prior year while still guiding to $13.00 to $13.25 in adjusted EPS. Ten-year total price return: 157.36%, before reinvested dividends.

When This Stock Underperforms APD lags badly in roaring risk-on markets. Over the past 30 days following Q2 earnings, the stock fell 6.92% while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) rose 5.69% and the Invesco QQQ Trust (NYSEARCA:QQQ) rose 11.74%. Helium pricing is a persistent headwind and the strategic reset under Menezes drove roughly $3.7 billion in FY2025 project exit charges. None of that changes the forever thesis, because the pipeline customers are still paying take-or-pay, the dividend is still rising, and the Samsung and NASA wins are still booked.

Air Products fits a long-horizon, income-focused portfolio.

BOSTON--(BUSINESS WIRE)--BXP (NYSE: BXP), the largest publicly traded developer, owner, and manager of premier workplaces in the United States, today announced a long-term lease agreement with Boston Dynamics for approximately 320,000 square feet at Reservoir Place, a 530,000 square foot building located at 1601 Trapelo Road in Waltham, Massachusetts. The lease marks one of the largest innovation-driven office transactions in Greater Boston this year and supports Boston Dynamics' plans for a si.

© Inspiration GP / Shutterstock.com

Few large-cap stocks have performed quite like Coinbase (NASDAQ:COIN | COIN Price Prediction) over the past 12 months. After peaking near $444.64 in the prior bull run, shares have round-tripped on a brutal crypto pullback. Our model sees significant upside from here.

Our 24/7 Wall St. price target for Coinbase is $271.94, implying 64.97% upside from the recent close of $164.84. The recommendation is buy, with a confidence level of 90%. That is a high-conviction call, anchored by forward earnings recovery, a deep subscription revenue base, and analyst consensus well above today’s quote.

24/7 Wall St. Price Target Summary Metric Value Current Price $164.84 24/7 Wall St. Price Target $271.94 Upside 64.97% Recommendation BUY Confidence Level 90% Crypto Winter Has Hit COIN Hard Coinbase shares are down 27.11% year to date and 46.55% over the past year, badly lagging the broader market. Bitcoin is down 27.05% YTD and Ethereum has tumbled 41.86%, squeezing the trading volumes that drive Coinbase’s transaction line.

Q1 2026 results, released May 7, 2026, showed the damage. Revenue of $1.41 billion fell 30.54% year over year, missing consensus by 4.72%. EPS came in at -$1.49 versus a $0.0444 estimate, weighed down by $482.40 million in markdowns on crypto held for investment. Management responded with a 14% headcount cut targeting roughly $500 million in annualized savings.

The Case for $400+ The bull case rests on Coinbase’s evolution beyond a pure trading venue. Subscription and services revenue reached 44% of net revenue in Q1, with stablecoin revenue of $305 million riding a USDC market cap that touched $80 billion in March.

Prediction markets crossed $100 million annualized within two months of launch, retail derivatives are tracking toward a $250 million tier, and DEX trading volume doubled quarter over quarter.

Industry tailwinds are sizeable. The stablecoin market is projected to grow from $300 billion to $3 trillion by 2030, with tokenized real-world assets potentially reaching $16 trillion.

If Coinbase rides those waves, our bull case scenario points to $406.07 over the next 12 months. Analyst consensus sits at $229.74, with 21 buys against just 3 sells.

What Could Go Wrong Coinbase remains tethered to crypto prices. Total crypto market cap and volumes both fell more than 20% quarter over quarter in Q1, and a beta of 3.32 means downside in BTC and ETH translates into amplified equity moves.

Insiders have been net sellers across 90 recent transactions, and the forward P/E of 77 leaves no room for further volume erosion.

The Q1 GAAP loss was largely a non-cash crypto markdown, and adjusted EBITDA was still positive at $303.30 million, the 13th straight positive quarter.

Cash of $10.21 billion and $2.10 billion in remaining buyback authorization give management room to defend the stock. Our bear case scenario still lands at $227.99, above today’s price.

Coinbase Price Prediction 2026-2030 My 24/7 Wall St. price target is $271.94, buy, with 90% confidence. The factor tipping the scale is the durability of subscription revenue, which now cushions trading swings far better than during the 2022 cycle.

The setup looks constructive if BTC stabilizes above $60,000 and Q2 transaction revenue tracks management’s $215 million May 5 pace. Caution is warranted if stablecoin revenue rolls over or another data-security event hits the cost base.

Year 24/7 Wall St. Price Target 2026 $221.08 2027 $271.94 2028 $365.00 2029 $490.00 2030 $645.59 These projections assume Coinbase executes its Everything Exchange strategy and stablecoin and prediction-market revenue compound through the decade. Significant upside or downside could result from crypto cycle timing, regulatory shifts under the GENIUS Act framework, or a major security incident.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© mixmotive / iStock Editorial via Getty Images

S&P Global (NYSE:SPGI | SPGI Price Prediction) screens as a multi-decade compounder candidate because it operates a legally protected toll booth on global capital markets that almost every borrower, asset manager, and index fund is structurally required to pay.

Recent price action is ugly: shares are down 23.08% year to date and trade at $400.16. For an investor in their 50s or 60s who has been chasing the wrong themes for a decade, that drawdown represents an entry point for long-horizon investors.

Pillar 1: Durability Backed by Regulation S&P Global is one of the Big Three credit rating agencies designated as an NRSRO by the SEC, a status required for most debt issuance in U.S. capital markets. Whenever a corporation, municipality, or sovereign government wants to issue debt, they are practically forced to pay S&P Global to rate it. The company also owns the S&P 500 and S&P Dow Jones Indices, collecting asset-linked licensing fees from essentially every major ETF and passive fund that tracks them.

The financial signature of that moat is unmistakable. Q1 2026 revenue grew 10.43% to $4.171 billion, GAAP operating margin expanded 620 basis points to 48.0%, and the Indices segment alone ran a 72% GAAP operating margin. Forward P/E sits at 21.

Pillar 2: Income That Compounds Quietly The Q4 2025 release marked the company’s 53rd consecutive year of dividend increases, putting it in Dividend King territory. The quarterly payout has climbed from $0.245 in 2001 to $0.97 today. Management plans to return 100% or more of adjusted free cash flow through dividends and buybacks in 2026, after returning $6.2 billion (113% of adjusted FCF) in 2025. Diluted shares are shrinking by roughly 3% a year.

Pillar 3: Built to Survive Market Cycles Recurring revenue absorbs the shocks. Subscription revenue grew 6% in Q1 2026, asset-linked index fees rose 18%, and surveillance fees on the trillions of dollars of already-rated debt keep flowing whether or not new issuance is hot. CEO Martina Cheung said the company delivered “strong revenue growth and margin expansion in every division” in “an incredibly volatile and challenging operating environment.”

The Scenario Where It Underperforms The Ratings business is cyclical. When credit markets freeze, transaction revenue drops fast, as it did in Q2 2025 when Ratings transaction revenue fell 4% and the segment grew just 1%. In a sustained issuance drought, SPGI will lag faster-growing software peers for several quarters. That does not break the forever thesis. Debt eventually gets refinanced, the NRSRO designation is not going away, and the S&P 500 brand is not displaceable by a competitor. Subscriptions, surveillance fees, and index licensing carry the company through the trough.

For a retirement-focused investor who is tired of watching screens, S&P Global fits the profile of a long-duration compounder rather than a short-term trade.